J&J funding project in dementia and Down syndrome; NextBio is developing biomarkers in AML;

> According to a report in Reuters, Johnson & Johnson ($JNJ) is funding a three-year study of dementia and Down syndrome in an effort to develop treatments, and also to crack open some of the secrets of Alzheimer's disease. Up to 75% of people with Down syndrome develop dementia that is similar to Alzheimer's disease, but the symptoms can begin as early as in their 40s and 50s. Article

> Bad breath bacteria don't just lose you friends--they could mark your risk of developing prostate cancer. Article

> NextBio and Emory University have teamed up to use biomarkers and translational medicine to develop treatments for multiple myeloma. Press release

> A blood test for two protein biomarkers has the potential to predict premature birth. Article

> Eutropics Pharmaceuticals has signed a contract with the National Cancer Institute to develop a companion diagnostic for personalized medicine in acute myelogenous leukemia (AML). Press release

> A panel of biomarkers is more effective than DNA alone to check out the involvement of human papillomavirus (HPV) in cases of head and neck cancers. Article

And Finally… Psychopaths could be marked by their impaired sense of smell--so watch out for that person who just can't stop and smell the roses. Press release

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.